Cage-like complexes formed by DOTAP, Quil-A and cholesterol

Lendemans, Dirk G.; Egert, A.M.; Hook, Sarah; Rades, Thomas

doi:10.1016/j.ijpharm.2006.09.029

Cited by 13 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous reports, different strategies were proposed to increase the charge of cage‐like particles. The cationic phospholipids N‐[1‐(2,3‐dioleoyloxy)propyl]‐N,N,N‐trimethylammonium methyl‐sulfate(DOTAP) and 3ß‐[N‐(N’,N’‐dimethylaminoethane)‐carbamoyl]cholesterol hydrochloride (DC cholesterol) have been incorporated to obtain partially or completely positive particles, respectively . Only the latter strategy was immunologically assessed.…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, in general terms, the importance of the association between antigen and adjuvant has been widely shown to enhance the action of different kinds of antigens and adjuvants . Accordingly, some authors have proposed increasing the surface charge of cage‐like particles to improve antigen adsorption . To modify the charge of these particles, positive phospholipids or cationic cholesterol derivative has been used.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and assessment of a new cage-like particle adjuvant

Bertona

Pujato

Bontempi

et al. 2017

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development and assessment of a new cage-like particle adjuvant

Bertona

Pujato

Bontempi

et al. 2017

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…Their hydrophobic “tail” regions are considerably different; DOTAP comprises two unsaturated hydrocarbon chains of equal length to DDA (C18) and a main phase transition temperature of −12 °C, resulting in a fluid lipid bilayer at physiological temperatures; in contrast, the cholesterol backbone of DC-Chol composed of numerous planar rings forms a more rigid bilayered structure. The structural similarity between cholesterol and DC-Chol has led to its more recent use as a cholesterol replacement in other lipid based constructs such as the ISCOM structures Posintro and PLUSCOMs. , Only very few studies have, however, been conducted comparing the immunostimulatory capacities of different cationic lipids. In the present study we characterized liposomes composed of DDA, DOTAP, or DC-Chol.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Depot Effect and Immunogenicity of Liposomes Based on Dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged Liposome Retention Mediates Stronger Th1 Responses

et al. 2010

View full text Add to dashboard Cite

The immunostimulatory capacities of cationic liposomes are well-documented and are attributed both to inherent immunogenicity of the cationic lipid and more physical capacities such as the formation of antigen depots and antigen delivery. Very few studies have however been conducted comparing the immunostimulatory capacities of different cationic lipids. In the present study we therefore chose to investigate three of the most well-known cationic liposome-forming lipids as potential adjuvants for protein subunit vaccines. The ability of 3β-[N-(N',N'-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), and dimethyldioctadecylammonium (DDA) liposomes incorporating immunomodulating trehalose dibehenate (TDB) to form an antigen depot at the site of injection (SOI) and to induce immunological recall responses against coadministered tuberculosis vaccine antigen Ag85B-ESAT-6 are reported. Furthermore, physical characterization of the liposomes is presented. Our results suggest that liposome composition plays an important role in vaccine retention at the SOI and the ability to enable the immune system to induce a vaccine specific recall response. While all three cationic liposomes facilitated increased antigen presentation by antigen presenting cells, the monocyte infiltration to the SOI and the production of IFN-γ upon antigen recall was markedly higher for DDA and DC-Chol based liposomes which exhibited a longer retention profile at the SOI. A long-term retention and slow release of liposome and vaccine antigen from the injection site hence appears to favor a stronger Th1 immune response.

show abstract

“…Moreover, this formulation was observed to be much effectual on the parasite than the drug alone. Immunostimulant complexes (ISCOM) (Morein et al, 1984), are lipids comprising of Quillaja Saponaria of homogeneous size (40 nm) that are used as adjuvants for vaccines (Wilson et al, 2014), namely antigen carriers, DNA vaccines for administration in oral and intranasal route (Lendemans et al, 2007;Sun et al, 2009). ISCOM encapsulated actinomycin D with antibodies resulted in dose-dependent effects (Cruz-Bustos et al, 2012) and were found to be more effective compared to antibiotic alone, indicating this formulation as a very potent nanocarrier for anti-trypanosomal therapy.…”

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

Nano-Medicines a Hope for Chagas Disease!

Choudhury

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Chagas disease, is a vector-mediated tropical disease whose causative agent is a parasitic protozoan named Trypanosoma cruzi. It is a very severe health issue in South America and Mexico infecting millions of people every year. Protozoan T. cruzi gets transmitted to human through Triatominae, a subfamily of the Reduviidae, and do not have any effective treatment or preventative available. The lack of economic gains from this tropical parasitic infection, has always been the reason behind its negligence by researchers and drug manufacturers for many decades. Hence there is an enormous requirement for more efficient and novel strategies to reduce the fatality associated with these diseases. Even, available diagnosis protocols are outdated and inefficient and there is an urgent need for rapid high throughput diagnostics as well as management protocol. The current advancement of nanotechnology in the field of healthcare has generated hope for better management of many tropical diseases including Chagas disease. Nanoparticulate systems for drug delivery like poloxamer coated nanosuspension of benzimidazole have shown promising results in reducing toxicity, elevating efficacy and bioavailability of the active compound against the pathogen, by prolonging release, thereby increasing the therapeutic index. Moreover, nanoparticle-based drug delivery has shown promising results in inducing the host’s immune response against the pathogen with very few side effects. Besides, advances in diagnostic assays, such as nanosensors, aided in the accurate detection of the parasite. In this review, we provide an insight into the life cycle stages of the pathogen in both vertebrate host and the insect vector, along with an overview of the current therapy for Chagas disease and its limitations; nano carrier-based delivery systems for antichagasic agents, we also address the advancement of nano vaccines and nano-diagnostic techniques, for treatment of Chagas disease, majorly focusing on the novel perspectives in combating the disease.

show abstract

Cage-like complexes formed by DOTAP, Quil-A and cholesterol

Cited by 13 publications

References 11 publications

Development and assessment of a new cage-like particle adjuvant

Development and assessment of a new cage-like particle adjuvant

Comparison of the Depot Effect and Immunogenicity of Liposomes Based on Dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged Liposome Retention Mediates Stronger Th1 Responses

Nano-Medicines a Hope for Chagas Disease!

Contact Info

Product

Resources

About